Stockscreener 앱 받기
2.11
6.22%
-0.14
시간 외 거래:
2.15
0.04
+1.90%
전일 마감가:
$2.25
열려 있는:
$2.25
하루 거래량:
4.78M
Relative Volume:
7.34
시가총액:
$82.52M
수익:
$832.00K
순이익/손실:
$-135.12M
주가수익비율:
-0.3465
EPS:
-6.09
순현금흐름:
$-124.69M
1주 성능:
+7.65%
1개월 성능:
+5.50%
6개월 성능:
+12.83%
1년 성능:
-72.81%
1일 변동 폭
$2.02
$2.265
1주일 범위
$1.86
$2.2989
52주 변동 폭
$1.42
$12.33
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
명칭
Inovio Pharmaceuticals Inc
전화
(858) 410-3134
주소
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
INO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
2.11 | 82.52M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2024-01-25 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-11-09 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-11-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-19 | 재개 | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-12-29 | 재개 | Jefferies | Hold |
| 2021-09-10 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-06-24 | 개시 | Jefferies | Hold |
| 2021-03-23 | 개시 | BofA Securities | Neutral |
| 2021-02-12 | 개시 | Oppenheimer | Outperform |
| 2020-11-17 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-11-10 | 업그레이드 | ROTH Capital | Sell → Neutral |
| 2020-09-28 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-07-01 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-06-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-21 | 개시 | The Benchmark Company | Buy |
| 2020-04-30 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-03-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | 개시 | ROTH Capital | Buy |
| 2018-02-15 | 재확인 | Maxim Group | Buy |
| 2017-10-18 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-06 | 개시 | Citigroup | Buy |
| 2017-06-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | 재확인 | Maxim Group | Buy |
| 2017-03-16 | 업그레이드 | Maxim Group | Hold → Buy |
| 2017-03-16 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
모두보기
Inovio Pharmaceuticals Inc 주식(INO)의 최신 뉴스
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2025 Earnings Call Transcript - MSN
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - AllSides
Human DNA Vaccines Market Set to Witness Breakthrough Advances - openPR.com
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Position Boosted by Bank of America Corp DE - Defense World
Deutsche Bank AG Has $164,000 Stock Holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
Northern Trust Corp Grows Holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio’s SWOT analysis: dna immunotherapy firm faces crucial year for stock - Investing.com Australia
Inovio shareholders approve board nominees and proposals By Investing.com - Investing.com Canada
Inovio shareholders approve board nominees and proposals - Investing.com Australia
Inovio Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
INOVIO Reports Q1 2025 Results and Key Developments in DNA Medicines - MyChesCo
Q2 EPS Estimate for Inovio Pharmaceuticals Cut by Analyst - Defense World
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Inovio Pharmaceuticals’ Earnings Call: Progress Amid Challenges - TipRanks
Inovio Pharmaceuticals (INO) Sees Price Target Adjustment by Opp - GuruFocus
Inovio outlines BLA submission timeline for INO-3107 and reports $68.4M cash position while advancing DNA medicine pipeline - MSN
Inovio Pharmaceuticals (INO) Maintains Sector Perform Rating by RBC Capital | INO Stock News - GuruFocus
Oppenheimer cuts Inovio stock price target to $13 By Investing.com - Investing.com Nigeria
INO Reports Strong Q1 Revenue, Progress on INO-3107 Submission | - GuruFocus
Inovio (INO) Receives Revised Price Target from Oppenheimer | IN - GuruFocus
Inovio Pharmaceuticals: Hold Rating Due to Financial Losses and Uncertain Development Timeline - TipRanks
Inovio stock holds $12 target, JMP affirms Market Outperform By Investing.com - Investing.com Canada
Inovio stock holds $12 target, JMP affirms Market Outperform - Investing.com Australia
Inovio Pharmaceuticals Inc (INO) Q1 2025 Earnings Call Highlights: Strategic Cost Management ... - Yahoo Finance
Inovio Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Inovio Pharmaceuticals (INO) Advances BLA Submission for INO-310 - GuruFocus
INOVIO Reports First Quarter 2025 Financial Results and Recent B - GuruFocus
Earnings call transcript: Inovio’s Q1 2025 sees narrowed losses, stock rises - Investing.com India
Inovio: Q1 Earnings Snapshot - San Francisco Chronicle
Inovio Pharmaceuticals Inc (INO) Q1 2025 Earnings: EPS of -$0.51 - GuruFocus
Inovio Pharmaceuticals Q1 Operating Expenses USD 25.1 Million - marketscreener.com
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights - PR Newswire
Inovio Pharmaceuticals Q1 25 Earnings Conference Call At 4:30 PM ET - Nasdaq
Options Volatility and Implied Earnings Moves Today, May 13, 2025 - The Globe and Mail
Inovio Pharmaceuticals (NASDAQ:INO) Lowered to “Sell” Rating by StockNews.com - Defense World
Inovio Pharmaceuticals (INO) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Inovio at The Citizens JMP Life Sciences Conference: DNA Platform Progress - Investing.com Australia
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Shares Sold by Renaissance Technologies LLC - Defense World
Inovio Pharmaceuticals (NASDAQ:INO) Cut to Sell at StockNews.com - Defense World
INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025 - Kilgore News Herald
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
INOVIO to Announce Q1 2025 Results and Host Live Webcast on May 13 - MyChesCo
Inovio Pharmaceuticals Inc (INO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
1.70%
자본화:
|
볼륨(24시간):